Ixia

Olmesartan Medoxomil, the active ingredient in Ixia, is an angiotensin II receptor blocker (ARB) presented as an oral formulation for systemic use. It is prescribed to lower elevated blood pressure in adult patients with hypertension, helping to reduce the risk of cardiovascular complications associated with sustained high blood pressure. Ixia is marketed in the European Union and conforms to the relevant regulatory standards.

GNH USA supplies Ixia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality‑assurance protocols and provides reliable logistics, ensuring consistent product availability for global procurement programmes.

Olmesartan Medoxomil is used to treat conditions within the hypertension disease family, helping to control elevated arterial pressure.

Essential hypertension: reduces systolic and diastolic blood pressure, improving long‑term cardiovascular risk management. Renal hypertension: lowers blood pressure in patients with hypertension secondary to renal disease, supporting kidney function preservation. Hypertension with left ventricular hypertrophy: helps regress cardiac remodeling by maintaining optimal blood pressure levels.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain often occurring early in therapy. - Fatigue: general feeling of tiredness without exertion. - Nausea: upset stomach, sometimes with mild vomiting. - Upper respiratory tract infection: transient cold‑like symptoms. - Back pain: occasional muscular discomfort.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention. - Hyperkalemia: elevated blood potassium that can cause cardiac rhythm disturbances. - Acute kidney injury: sudden decline in renal function, indicated by reduced urine output or increased creatinine. - Severe hypotension: marked drop in blood pressure leading to fainting or shock. - Hepatic injury: abnormal liver enzymes or jaundice indicating liver stress.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: regularly check to ensure therapeutic targets are met. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with pre‑existing kidney disease. - Electrolyte balance: monitor potassium levels to avoid hyperkalemia. - Hepatic impairment: use caution in patients with moderate to severe liver disease. - Pregnancy and lactation: discuss potential risks with a healthcare professional before use. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Olmesartan Medoxomil may interact with several medicines. Review the following categories:

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use can increase risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous elevations in serum potassium. - ACE inhibitors: concurrent use raises the likelihood of angioedema and hyperkalemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - NSAIDs (e.g., ibuprofen): can attenuate the blood‑pressure‑lowering action and affect renal function.